GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of someone explain 503A to me like I have not read a paper in years — 39 comments in the full submission. View in context.
2.9k
c/compounding·submitted 2 years ago by u/kavya_kravchenko

someone explain 503A to me like I have not read a paper in years

Pricingbranch of 6 comments

someone explain 503A to me like I have not read a paper in years. I would rather ask a basic question now than get this wrong quietly for two months. Asked which facility and got a name straight away. Looked it up, found the registration, felt considerably better about the whole thing. The intake asked me three…

Read the full submission and all 39 comments →

This branch

6 comments, started 2 years ago
u/milos_mensa97 points·2 years ago

potency testing on the finished preparation is the thing to ask for

replysharereportpermalink
u/formulary_fighterMOD66 points·2 years ago

Removed the staff name. Facilities and clinics can be named here; individuals cannot.

replysharereportpermalink
u/rania_diallo97 points·2 years ago

Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.

replysharereportpermalink
u/kavya_kravchenkoOP69 points·2 years ago

Correction: patient-specific refers to the prescription, not to a bespoke formulation. Common misreading and it changes the argument.

replysharereportpermalink
u/lift_heavy_thingsresistance training0 points·2 years ago

Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.

replysharereportpermalink
u/ismael_pires79 points·2 years ago

Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.

replysharereportpermalink

← back to the whole thread

About c/compounding

Compounded GLP-1s as a supply route: the 503A/503B distinction, the shortage-list mechanics that made compounding legal and then didn't, state board rules, telehealth prescriber models, and what a compounding pharmacy will and will not tell you about its API source.

53kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/compounding
c/compounding rules
  1. Regulatory claims need a citation to the actual rule, notice or docket.
  2. No pharmacy referral codes. Naming a pharmacy is fine; recruiting for it is not.
  3. API source questions are on-topic and pharmacies dodging them is newsworthy.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/formulary_fighteru/usp_appendixu/quiet_moderatoru/prior_auth_pain
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →